MA
BCAB icon

MYDA Advisors’s BioAtla BCAB Stock Holding History

MYDA Advisors’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,000
Closed -$137K – 149
2024
Q2 		$137K Sell
2,000
-1,600
-44% -$190K 0.03% 117
2024
Q1 		$619K Sell
3,600
-800
-18% -$99.4K 0.18% 80
2023
Q4 		$541K Buy
4,400
+3,600
+450% +$312K 0.18% 65
2023
Q3 		$68K Sell
800
-400
-33% -$51K 0.02% 102
2023
Q2 		$180K Buy
1,200
+100
+9% +$17.2K 0.05% 103
2023
Q1 		$147K Buy
+1,100
New +$198K 0.06% 102
2022
Q3 		– Sell
-1,480
Closed -$211K – 159
2022
Q2 		$211K Buy
1,480
+280
+23% +$44.6K 0.06% 156
2022
Q1 		$300K Buy
+1,200
New +$502K 0.12% 145

Other funds holding BCAB

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

MYDA Advisors's BCAB Position: Q3 2024 in Review

MYDA Advisors sold out of BioAtla (BCAB) in Q3 2024, closing a stake of 2,000 shares — an estimated $137K sold.

MYDA Advisors first reported a position in BCAB in Q1 2022 and held it in 8 quarters. The position peaked at $619K in Q1 2024. 63 funds tracked by Wall St. Rank hold BCAB as of Q3 2024.

  • MYDA Advisors reported no remaining BioAtla position as of Q3 2024 after selling out during the quarter.
  • MYDA Advisors sold 2,000 BioAtla shares in Q3 2024, an estimated $137K.
  • MYDA Advisors first reported a position in BioAtla in Q1 2022 and held it in 8 quarters.
  • MYDA Advisors's BioAtla position peaked at $619K in Q1 2024.
  • 63 funds tracked by Wall St. Rank held BioAtla as of Q3 2024.

Based on MYDA Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.